✦ LIBER ✦

Endocrine therapy of advanced carcinoma of the prostate

✍ Scribed by Firouz Daneshgari; E. David Crawford

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 919 KB
Volume: 71
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19930201)71:3+<1089::aid-cncr2820711431>3.0.co;2-h

No coin nor oath required. For personal study only.

✦ Synopsis

Increasing evidence suggests that growth of the prostatic tissue is regulated by a network of hormones and growth factors, in which androgens play the prominent role. Hormonal manipulation remains the core of treatment for locally advanced and metastatic prostate cancer. Achievement of a complete androgen blockade, by surgical or medical means or a combination of both, offers superior results in palliative management of advanced disease. Management of hormonal refractory cancer, however, remains a challenge to clinicians. Cancer 1993: 71:1089-97.

📜 SIMILAR VOLUMES

Intermittent endocrine therapy for advan

Intermittent endocrine therapy for advanced prostate cancer

✍ Laurence H. Klotz; Harry W. Herr; Michael J. Morse; Willet F. Whitmore Jr. 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 491 KB 👁 1 views

Twenty patients with advanced prostate cancer have been treated with an intermittent endocrine therapy schedule. Hormone therapy (diethylstilbestrol in 19 patients and flutamide in 1 patient) was administered until a clinical response was clearly demonstrated and then it was withheld until symptoms

Localized advanced carcinoma of the pros

Localized advanced carcinoma of the prostate: Radiation therapy versus hormonal therapy

✍ Brigit Van Der Werf-Messing; Vera Sourekzikova; Dirk I. Blonk 📂 Article 📅 1976 🏛 Elsevier Science 🌐 English ⚖ 489 KB

Hormonal Therapy for Advanced Prostatic

Hormonal Therapy for Advanced Prostatic Carcinoma

✍ Allen D. Seftel; J. Patrick Spirnak; Martin I. Resnick 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 841 KB

Since the work of Huggins and Hodges, hormonal therapy, i.e., orchiectomy or estrogens, has been the gold standard of treatment for patients with advanced adenocarcinoma of the prostate. Recently, many new drugs have been introduced in the hope of achieving a beneficial response as compared with hor

Buserelin as primary therapy in advanced

Buserelin as primary therapy in advanced prostatic carcinoma

✍ Cary A. Presant; Mark S. Soloway; Sol S. Klioze; John W. Kosola; Alun L. Yakabow 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 2 views

A histological explanation for the benef

A histological explanation for the beneficial action of endocrine therapy in carcinoma of the prostate

✍ Professor T. Nicol; I. D. Helmy; A. Abou-Zikry 📂 Article 📅 1952 🏛 John Wiley and Sons 🌐 English ⚖ 908 KB

Steroid receptor content in human prosta

Steroid receptor content in human prostatic carcinoma and response to endocrine therapy

✍ Peter Ekman; Marek Snochowski; Anders Zetterberg; Bertil Högberg; Jan-Åke Gustaf 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 782 KB

Biopsy material from primary prostatic carcinoma from 25 patients was analyzed with regard to cytosol content of methyltrienolone (a synthetic androgen) binding sites and the receptor content has been correlated to the clinical response to endocrine therapy. A dextran-coated charcoal technique was u